The following discussion should be read in conjunction with our audited
consolidated financial statements and notes thereto for the fiscal year ended
Financial Highlights
During fiscal 2020, we made significant progress in the advancement of clinical studies for ANAVEX®2-73, including continued enrollment of our Phase 2b/3 Alzheimer's disease trial and expansion of this trial internationally, completion of our proof-of-concept Phase 2 Parkinson's disease dementia trial, continued advancement of a multi-regional Phase 2/3 clinical program for the treatment of Rett syndrome, including completion of the Phase 2 U.S. trial and expansion of the AVATAR Phase 2 study internationally and the commencement of the EXCELLENCE Phase 2/3 pediatric Rett syndrome study. While fiscal 2020 was marked by the outbreak of COVID-19, which temporarily slowed down activities in many of the countries in which these trials are taking place, our clinical trials were able to continue largely uninterrupted in compliance with local regulations and policies, and we were able to continue to recruit and screen new patients as much as possible to advance these studies. Additionally, we commenced the first in human Phase 1 clinical trial of ANAVEX®3-71 during fiscal 2020 with focus on the treatment of Frontotemporal Dementia (FTD) and other dementia indications with unmet medical need.
As a result, our operating expenses for fiscal 2020 increased to
During fiscal 2020, we utilized
We continue to see an increase in our research and development expenditures as
we advance our ANAVEX®2-73 clinical studies, including adding extension studies
to allow us to continue to gather longer term data, and adding additional
staffing to manage the clinical studies currently underway. We also continue to
receive support from the Australian government for various clinical trials being
conducted within
In
Net loss for fiscal 2020 was
39 Results of Operations Revenue
We are in the development stage and have not earned any revenues since our inception. We do not anticipate earning any revenues until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.
Year ended
Operating Expenses
Total operating expenses for the year ended
Research and development expenses for fiscal 2020 were
During fiscal 2020 our general and administrative expenses were
Other income
The net amount of other income for the year ended
Net loss for fiscal 2020 was
Liquidity and Capital Resources
Working Capital
2020 2019 Current Assets$ 34,542,197 $ 25,329,373 Current Liabilities 7,305,628 5,039,674 Working Capital$ 27,236,569 $ 20,289,699
At
We intend to continue to use our capital resources to advance our clinical trials for ANAVEX®2-73, and to perform work necessary to prepare for future development of our pipeline compounds.
40 Cash Flows 2020 2019
Cash flows used in operating activities
$ 7,063,388 $ (745,008)
Cash flow used in operating activities
There was an increase in cash used in operating activities of
Cash flow provided by financing activities
Cash provided by financing activities for fiscal 2020 was related to cash
received from the issuance of shares under the 2019 Purchase Agreement and the
Sales Agreement, as more fully described below. During fiscal 2020, we issued an
aggregate of 9.4 million shares for gross proceeds of
Other Financings Purchase Agreement
On
We may direct Lincoln Park, at our sole discretion, and subject to certain
conditions, to purchase up to 200,000 shares of common stock on any business day
(a "Regular Purchase"). The amount of a Regular Purchase may be increased under
certain circumstances up to 250,000 shares provided that Lincoln Park's
committed obligation for Regular Purchases on any business day shall not exceed
At
41
Controlled Equity Offering Sales Agreement
On
Upon delivery of a placement notice based on our instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell shares of common stock by methods deemed to be an "at the market offering", in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to our prior written consent. We are not obligated to make any sales of shares under the Sales Agreement. We or the Sales Agents may suspend or terminate the At-the-Market Offering upon notice to the other party, subject to certain conditions. The Sales Agents will act as agents on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of Nasdaq.
We have agreed to pay the Sales Agents commissions for their services of 3.0% of
the gross proceeds from the sale of the Shares pursuant to the Sales Agreement.
We have also agreed to provide the Sales Agents with customary indemnification
and contribution rights. At
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.
42
Application of Critical Accounting Policies
Our financial statements and accompanying notes are prepared in accordance with
generally accepted accounting principles in
We base our assumptions and estimates on historical experience and other sources that we believe to be reasonable at the time. Actual results may vary from our estimates due to changes in circumstances, politics, global economics, general business conditions and other factors. Our significant estimates are related to the valuation of warrants and options.
There are accounting policies that we believe are significant to the presentation of our financial statements. The most significant of these accounting policies relates to the accounting for our research and development expenses and stock-based compensation expense.
Research and Development Expenses
Research and development costs are expensed as incurred. These expenses are comprised of the costs of the Company's proprietary research and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and stock based compensation expense, contract services including external research and development expenses incurred under arrangements with third parties such as contract research organizations ("CROs"), facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification ("ASC") 730, Research and Development, as these materials have no alternative future use outside of their intended use.
Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs incurred in relation to external CROs, and clinical site costs. The Company analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. The Company reviews and accrues CRO expenses and clinical trial study expenses based on work performed and relies upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to record expenses in our financial statements based on actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.
In addition, we incur expenses in respect of patents and trademarks. The probability of success and length of time to develop commercial applications of the compounds subject to the underlying patents and trademarks is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development projects. There is no assurance the compounds subject to the underlying patents and trademarks will ever be successfully commercialized. Due to these risks and uncertainties, we expense the patent and trademark costs within general and administrative expenses in our financial statements.
Stock-based Compensation
We account for all stock-based payments and awards under the fair value-based method.
We account for the granting of share purchase options and warrants to employees using the fair value method whereby all awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options and warrants are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.
Share purchase options and warrants issued to non-employees are measured at the
fair value of the equity instruments issued. Compensation expense for share
purchase options and warrants issued to non-employees is recorded over the
service performance period. Prior to our adoption of ASU No. 2018-07,
Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee
Share-Based Payment Accounting on
Compensation costs for stock-based payments with graded vesting are recognized on a straight-line basis.
We use the Black-Scholes option valuation model to calculate the fair value of share purchase options and warrants at the date of the grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes in these assumptions can materially affect the fair value estimates.
For a discussion of recent accounting pronouncements and their possible effect on our results, see Note 2(n) to our Consolidated Financial Statements found elsewhere in this Annual Report.
43
© Edgar Online, source